These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25600263)

  • 1. Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease.
    Ha C; Mathur J; Kornbluth A
    Expert Rev Gastroenterol Hepatol; 2015 Apr; 9(4):497-505. PubMed ID: 25600263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB
    Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases.
    Billmeier U; Dieterich W; Neurath MF; Atreya R
    World J Gastroenterol; 2016 Nov; 22(42):9300-9313. PubMed ID: 27895418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
    Leung Y; Hanauer SB
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S202-8. PubMed ID: 20117343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.
    Renna S; Cottone M; Orlando A
    World J Gastroenterol; 2014 Aug; 20(29):9675-90. PubMed ID: 25110407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased arterial stiffness in inflammatory bowel diseases is dependent upon inflammation and reduced by immunomodulatory drugs.
    Zanoli L; Rastelli S; Inserra G; Lentini P; Valvo E; Calcagno E; Boutouyrie P; Laurent S; Castellino P
    Atherosclerosis; 2014 Jun; 234(2):346-51. PubMed ID: 24732573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on idiopathic colitides.
    Strobel S; Abreu MT
    Curr Opin Gastroenterol; 2013 Jan; 29(1):60-5. PubMed ID: 23207597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.
    Androulakis I; Zavos C; Christopoulos P; Mastorakos G; Gazouli M
    World J Gastroenterol; 2015 Dec; 21(47):13205-11. PubMed ID: 26715803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J
    Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy.
    Ong DE; Kamm MA; Hartono JL; Lust M
    J Gastroenterol Hepatol; 2013 Oct; 28(10):1595-9. PubMed ID: 23662928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
    Lee TW; Fedorak RN
    Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inflammatory bowel disease].
    Patuto N; Beglinger C
    Praxis (Bern 1994); 2013 Aug; 102(17):1046-52. PubMed ID: 23965717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
    Orlando A; Armuzzi A; Papi C; Annese V; Ardizzone S; Biancone L; Bortoli A; Castiglione F; D'Incà R; Gionchetti P; Kohn A; Poggioli G; Rizzello F; Vecchi M; Cottone M; ;
    Dig Liver Dis; 2011 Jan; 43(1):1-20. PubMed ID: 20843756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors.
    Papi C; Fascì-Spurio F; Rogai F; Settesoldi A; Margagnoni G; Annese V
    Dig Liver Dis; 2013 Dec; 45(12):978-85. PubMed ID: 24018244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease.
    Torres J; Boyapati RK; Kennedy NA; Louis E; Colombel JF; Satsangi J
    Gastroenterology; 2015 Dec; 149(7):1716-30. PubMed ID: 26381892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.